Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy
2001
Anaemia in Cancer Patients: Challenges and Therapy Prospects
publication
Evidence: moderate
Author Information
Author(s): Demetri G D
Primary Institution: Dana-Farber Cancer Institute and Harvard Medical School
Hypothesis
Can recombinant human erythropoietin improve quality of life in anaemic cancer patients undergoing chemotherapy?
Conclusion
Recombinant human erythropoietin effectively increases haemoglobin levels in over half of anaemic cancer patients, leading to improved quality of life.
Supporting Evidence
- Anaemia contributes to reduced quality of life in cancer patients.
- Red blood cell transfusions have temporary benefits and associated risks.
- rHuEPO increases haemoglobin levels in over half of anaemic cancer patients.
- Increased haemoglobin levels correlate with improved quality of life.
- Less than 50% of anaemic cancer patients receive rHuEPO.
Takeaway
Anaemia is common in cancer patients and can make them feel worse, but a treatment called rHuEPO can help them feel better by increasing their blood levels.
Limitations
Less than 50% of anaemic patients receive rHuEPO due to various barriers.
Participant Demographics
Cancer patients undergoing chemotherapy.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website